Grail was formed following a spin-off from Illumina, and Morgan Stanley reiterated its 'Equal Weight' stance on the companies.
3 reports, 0 independent
Updated Jul 9
Gone quiet
- Reports
- 3
- Developments
- 1
- Repetition
- 67%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Grail was formed following a spin-off from Illumina, and Morgan Stanley reiterated its 'Equal Weight' stance on the companies.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
GRAIL
American biotechnology and pharmaceutical company
Nothing else this week.
-
Illumina
American company that develops systems for the analysis of genetic variation
-
Morgan Stanley
U.S. investment bank
- Multiple financial institutions, including Goldman Sachs, Morgan Stanley, Bank of America, UBS, and others, provided ratings and price targets for Marvell Technology on May 28, 2026.
- Goldman Sachs and Morgan Stanley noted that semiconductor stocks benefit from current rate levels but face market caution.
Coverage
Newest first; wire copies grouped- Unknown outlet
- Unknown outlet
- Unknown outlet